Navigation Links
Thermage Discloses Preliminary 3Q 2008 Results for Thermage and Reliant
Date:11/4/2008

Thermage Schedules Release Date and Conference Call

Pro Forma Combined Third Quarter 2008 Revenue Growth of 8%

HAYWARD, Calif., Nov. 4 /PRNewswire-FirstCall/ -- Thermage, Inc. (Nasdaq: THRM) today provided preliminary results for the third quarter ended September 30, 2008 for both Thermage and Reliant Technologies, Inc. The Company provided the preliminary results because it may update its Form S-4 filing with the Securities and Exchange Commission regarding the merger of the two companies prior to the issuance of its final third quarter results and any update would include the preliminary results for the third quarter. Thermage and Reliant expect to complete the merger of the two companies in the fourth quarter.

Thermage revenue for the third quarter is expected to be in the range of $12.9 to $13.0 million, compared with $13.9 million in the third quarter of 2007. The gross profit margin for the third quarter of 2008 is expected to be approximately 75% of revenue. The Company expects to report a net loss during the third quarter of 2008 of approximately $1.2 million on a GAAP basis. The net loss includes a loss of approximately $0.9 million on a Lehman Brothers corporate bond held in the Company's investment portfolio and approximately $0.9 million in stock-based compensation charges.

Third quarter 2008 revenue for Reliant is expected to be in the range of $19.7 to $20.0 million, representing a growth rate of approximately 21% over $16.3 million in revenue in the third quarter of the prior year. Reliant's operating loss for the third quarter of 2008 is expected to be between $1.6 and $1.8 million on a GAAP basis. The operating loss includes approximately $1.6 million in stock based compensation cha
'/>"/>

SOURCE Thermage, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Thermage, Inc. to Present at the Maxim Group Growth Conference
2. Thermage, Inc. Announces Distribution Agreement With Eclipse Medical, Ltd.
3. Thermage Announces Third Quarter Financial Results
4. Thermage, Inc. Appoints John F. Glenn as Chief Financial Officer
5. Thermage, Inc. Announces Fourth Quarter 2007 Results Release Date and Conference Call
6. Thermage Announces Fourth Quarter and Full Year 2007 Financial Results
7. Thermage, Inc. Announces Initial Shipments of Cellulite Product
8. Thermage, Inc. Announces First Quarter 2008 Results Release Date and Conference Call
9. Thermage, a Leading Aesthetic Medical Device Company, Announces First Time Exhibitor Status at ACOG Meeting
10. Thermage, Inc. to Present at the Bank of America 2008 Healthcare Conference
11. Thermage and Reliant Technologies to Join Forces

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...UILLY-SUR-SEINE,France,Nov.27/PRNewswire/--TeamGar...teamdedicatedtoethicalsportinganddevelopingthenext...illbecomeTeamGarmin-TransitionswiththeadditionofTr...Opticalistheworld,sleadingmanufacturerofadaptiveey...yinthewidestselectionofspectaclelensessuchasTransi...
(Date:11/27/2009)... XenaCare Holdings has announced th...is Foundation, one of the largest nonprofit organi... health education. , Delr... Holdings, Inc. (OTCBB: XCHO), a company specializ...nsumer healthcare products, has announced today th...
(Date:11/27/2009)...tes to bring unprecedented medical, economic burde...HealthDay News) -- The number of people with diabe...r the next 25 years, a new study predicts. , Th...lion people with the disease, up from 23.7 million...ng people with diabetes will triple, the study als...
(Date:11/27/2009)... Voyant Health™ announced tod...as licensed its TraumaCad Enterprise orthopedic te...w solution. , (PRWEB) Nov...oday that Spectrum Health (Grand Rapids, Michigan)...templating solution and its TraumaCad Extend workf...
(Date:11/27/2009)... Specialist manufacturers who use m...re saving millions of dollars by bringing in techn... Increasing numbers of pro-active medical manufact...the concept stage of their projects, ensuring that...gn processes or potentially outdated technology. ...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...nsula Medical School in the South West of England ...eel that doctors providing out of hours services i... Researchers held group discussions and carried ou...ngland. , Under the GP contract, which came into ...
... 29 CalbaTech, Inc.,(OTC Bulletin Board: CLBE), a...aTech.com ) concentrating on the collection and ba...apeutic uses and providing,products and platforms ...th has renewed LifeStem,s biologics license.,LifeS...
...Role as Governments and Civil Society in the ...Crisis, NEW DELHI, India, BEIJING and BANGKOK, Th...IDS Day 2007, hundreds, perhaps thousands, of men,...but ever-growing crisis that many governments in t...
...the hip is a growing problem that will continue to... have reported on risk factors for developing OA, ...ct its prognosis. A new study published in the Dec...r disease progression and to find out how many und...
...it has obtained agreement with the United States, ...n of its pivotal study, protocol for SP1049C for t... upper gastrointestinal tract, ...rsus BSC alone for the treatment of patients with ...
...) -- There are estimated to be between 50,000 --...ronic Immune Thrombocytopenic Purpura (ITP), an au...ber of platelets in their blood -- causing bruises...rk-Presbyterian Hospital/Weill Cornell Medical Cen...
Other Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 2Health News:CalbaTech Reports That LifeStem's Biologics License Has Been Renewed 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 2Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 3Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 4Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 5Health News:New Asia Pacific Statistics Reveal an Alarming Incidence of HIV in MSM 6Health News:Identifying patients at high risk for total hip replacement 2Health News:Supratek Pharma Inc. announced today that under the Special Protocol 2Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2
(Date:11/25/2009)...rstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),aclinical...evelopingandcommercializingnoveldrugstotreatvirali...endedSeptember30,2009.AtSeptember30,2009Pharmasset...investments. ,, PipelineUpdateand2009Highlight...ateNovember2009,anindependentDataMonitoringCommitt...
(Date:11/25/2009)...PRNewswire/-- FromNovember16-18,Phonak,theleadingm...hesecondeditionoftheHearingCareforAdultsConference...conferencebroughttogetherleadingexpertsinaginganda...whoworkeverydaywitholderpeoplewithhearinglossforan...searchandtrendsinhearingcareforolderpeople. ,,...
(Date:11/25/2009)...--TheFDAgrantedtraditionalapprovalforINTELENCE...riptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspe...ltswhoareexperiencingvirologicfailurewithHIV-1stra...ents.Thetraditionalapprovalisbasedon48-weekdatafro...scurrentlymarketedintheU.S.byTibotecTherapeutics,a...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 1Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 2Critical Signal Technologies Acquires Link to Life to Grow Depth and Expertise in TeleHealth Personal Emergency Response and Medical Monitoring Syste 57351 3AEterna Zentaris Partner Keryx Biopharmaceuticals Receives Orphan Drug Designation for Perifosine 28KRX 0401 29 for the Treatment of Multiple Myelo 14093 1AEterna Zentaris Partner Keryx Biopharmaceuticals Receives Orphan Drug Designation for Perifosine 28KRX 0401 29 for the Treatment of Multiple Myelo 14093 2AEterna Zentaris Partner Keryx Biopharmaceuticals Receives Orphan Drug Designation for Perifosine 28KRX 0401 29 for the Treatment of Multiple Myelo 14093 3Binghamton Research Group Develops New Cancer Treatment 5010 1Binghamton Research Group Develops New Cancer Treatment 5010 2Binghamton Research Group Develops New Cancer Treatment 5010 3Binghamton Research Group Develops New Cancer Treatment 5010 4
...nted At The American Society Of Clinical Psychopha... WELLESLEY HILLS, Mass., Sept. 15 Joseph F. Finn,...herics, Inc. ("Spherics") for,the benefit of credi...intellectual property will be sold at a sealed bid... adverse effects on cognitive functions at rates o...
...rom Phase 2 CEA and ACS Clinical Trials to be Rele...tation, SAN FRANCISCO, Sept. 15 VIA Pharmaceutic... focused on the development of,compounds for the t...y that,two abstracts on the company,s Phase 2 tria...drome (ACS) and in patients undergoing carotid,end...
Other Medicine Technology:Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R) 2VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008 2VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008 3VIA Pharmaceuticals to Present at American Heart Association Scientific Sessions 2008 4
...ested Timeter® Classic Flowmeters demonstrates...oviders and patients alike. You can see it in the ... can see it in the performance, year after year. E...d and engineered to the highest standards of perfo...
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/Y Bar & 2 Power Take Off
Soft-Touch Timeter® 15 LPM Dual Oxygen Flowmeter w/T Bar
Soft-Touch Timeter® 8 LPM Flowmeter
Medicine Products: